Bausch Health Companies
Valeant Pharmaceuticals had suffered a lot of road bumps in the past that caused its stocks to nosedive. Apart from huge debts, the brand also faced criticism and centered on accounting controversies, which was probably why it changed its name to Bausch Health Companies in 2018.
After an intricate facelift, Bausch Health’s stock has greatly improved in recent years. It had found an ally in Permian Investment Partners, a New York hedge fund that increased its position by 17 percent when it purchased 775K shares in the third quarter of 2020.
